Medical Affairs, Market Access, MSL

*

A

r

a

Aravind Patil, Cell: +1-437-***-****, Email: **.*******.*******@*****.***

Aravind Patil, MBBS, PhD

Brampton, L7A 0X7, Canada

Cell: +1-437-***-****, Email: **.*******.*******@*****.*** PROFESSIONAL SUMMARY

A physician with over 2+ years of Medical Affairs experience in Canada and 6+ years of experience in international markets in innovator companies (Pfizer, Taiho/Otsuka). Experienced in therapeutic areas of Vaccines, Immunology, Oncology, and hematology. Experienced in market research, epidemiological studies, advisory boards, investigator trials, real-world evidence generation, publications, etc. Education in clinical medicine (MBBS), Research Immunology (Ph.D.), and management (MBA). CORE COMPETENCIES and ACHIEVEMENTS

• Advanced Scientific knowledge of Clinical Medicine and Research: Bachelor’s degree in medicine (MBBS), doctorate (Ph.D.) in biotechnology, and MBA from India`s leading B-school. Expertise in Oncology, Hematology, Immunology, and Vaccines.

• Experience in Medical affairs:

Managed speaker programs, and investigator-initiated trials in Canada. Conducted advisory board programs, MSL/sales training, etc. Developed CME contents.

• Experience of Market access:

Introduced first-to-market generic products in international markets: Azacitidine, Bortezomib, Rituximab. Understanding of Canadian Market Access, IMC code, and Healthcare Compliance policies.

• Credentials:

Published research articles on hepatitis and dengue vaccine technologies and Author of a patent on a candidate dengue vaccine outsourced to Sun Pharma for development (please refer to the last page)

Associate editor for a scientific journal (Vaccines & Immunology, Ology press) WORK EXPERIENCE

Medical Advisor – Hematology and Solid tumors (on contract) Nov 2019 to Nov 2021 Taiho Pharma Canada (part of Otsuka group), Oakville, ON, Canada

• Strategy development: Developed medical strategy and contributed to the development of Brand Strategy for marketed products (LONSURF® & INQOVI®).

• Regulatory affairs: Assisted MD in developing NDS/SNDS submissions in coordination with regulatory.

• KOL engagement: Managing KOL relationships. Conducted two speaker programs (train the trainer) and slide deck development with a group of pan-Canada oncologists/hematologists. Trained speakers for sponsored educational activities. Organized advisory boards, consultancy meetings, and speaker tours.

• Investigator Initiated Trials (IITs): Supported Phase 2 & RWE studies. Reviewed research proposals, managed contracts, budget projections, and drug supply chain.

• Training: Developed and conducted disease area (MDS/AML) & product monograph training for salesforce. Conducted internal training and journal clubs for MSLs. Developed CME program contents.

2

A

r

a

Aravind Patil, Cell: +1-437-***-****, Email: **.*******.*******@*****.***

• Market access: Assisted in developing pCODR submission files. Addressed queries from pCODR.

• Medical information: Developed standard responses and FAQs responses, trained the medical information associates at the call center. Covered conferences for competitive intelligence. Business Development Advisor Jan 2019 – Aug 2019

Pharmaris & TVR Pharmaceutical Inc, Vancouver, Canada Conducted market research, competitor landscaping, and formulary pricing analysis. Developed business plans. Negotiated with contract drug manufacturers for the in-licensing of products. Developed marketing materials and addressed queries from PAAB. Manager Market Access – Oncology & Hematology May 2016 – July 2018 Dr. Reddy’s Laboratories, India

• Supported launch of oncology products for Hematological malignancies (Azacitidine, Bortezomib, Rituximab) and solid tumors (Pemetrexed, Fulvestrant, Abiraterone).

• Was responsible for developing market access for North African markets: Algeria, Morocco Tunisia: Researched healthcare landscape (epidemiology, key accounts, regulatory picture, reimbursement landscape, etc.)

o Conducted therapeutic and scientific training of sales personnel, key account managers o Reviewed promotional plans. Secured company`s first tender in Algeria ($ 2.1 Million) Scientific Advisor Feb 2013 – March 2015

Phamax, India

• Coordinated Phase IV/RWE study for a novel COPD drug for Takeda Europe. Liaise with stakeholders, managed communications developed eCRF, Reviewed interim study reports, and publications

• Conducted retrospective Health Economics study for chronic hepatitis complications Client: MSD. Conducted direct and indirect cost analysis and developed budget impact models.

• Epidemiological analysis and Advocacy project (chronic hepatitis: HBV/HCV) Client: MSD. Conducted primary and secondary epidemiological research. Mapped and engaged ~90 stakeholders (HCPs, patient organizations, physician bodies, regulatory). Conducted regional congresses and conferences.

• Developed Morocco market access strategy for Adcetris® a Hodgkin`s lymphoma biologic. Client: Takeda. Conducted market research (epidemiology, treatment practice, patient journey and outcomes, reimbursement landscaping, and key stakeholder analysis). Medical Science Liaison – Vaccines (Prevenar-13) March 2012 –Feb 2013 Pfizer India Ltd, India

Fostered peer to peer relationships with KOls. Engaged KOLs through medical programs.

• Developed academic collaboration between Pfizer and Narayana Hrudayalaya hospital, Bangalore

• Supported investigator-initiated research for surveillance of invasive pneumococcal infections

• Trained >100 sales representatives on scientific aspects of products. Scientific information dissemination: Presented in >90 medical education programs (CMEs) EDUCATION

• Graduate Diploma: Pharmaceutical & Healthcare Management and Innovation (PHMI) Queen`s University, Canada 2019 2020

• Certification: Pharmaceutical Market Access in Canada Council for Continuing Pharmaceutical Education (CCPE), Canada 2019 3

A

r

a

Aravind Patil, Cell: +1-437-***-****, Email: **.*******.*******@*****.***

• Diploma Vaccinology - Institute Pasteur, Paris, France 2013

• MBA, Indian School of Business (ISB), India 2015 2016

• PhD (Dengue & Hepatitis vaccines/Immunology) 2007 2011 International Centre for Genetic Engineering and Biotechnology, India

• MBBS (Medicine), Rajiv Gandhi University of Health Sciences, India 2001 – 2007

• Project Management Professional (PMP) 2019 – 2023 PATENT & PUBLICATIONS

• Patent: Currently being developed by Sun pharmaceutical, India Envelope domain III based dengue vaccine candidate using HBsAg virus-like particles as the modular display system, 2010. (INDIA 1820/DEL/2010)

• Novel membrane extraction procedure for the purification of Hepatitis B surface antigen from Pichia pastoris. Patil. A and Khanna. N; J of chromatography B (Elsevier journal), 898, 1 June 2012, pg 7-14

• Dengue-specific sub-viral nanoparticles: design, creation & characterization; Aravind Patil et al; J of Nanobiotechnology, May-13

• Healthcare cost and access to care for viral hepatitis in Ethiopia; Aravind Patil et al; International Journal of Innovation and Applied Studies, Volume 9, Issue 4, December 2014, Pages 1718–1723

• Hepatitis awareness among the general public in Cameroon: A survey study; Aravind Patil et al; International Journal of Innovation and Applied Studies, Vol. 8 No. 3 Sep. 2014, pp. 1370-1376

Contact this candidate